Return to homepagePandemic Pact

Development of Anti-COVID-19 Peptide Drugs [Funder: Carleton University COVID-19 Rapid Research Response Grants]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Ashkan Golshani

  • Research Location

    Canada

  • Lead Research Institution

    Carleton University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We plan to make directed peptides capable of interfering with the replication of the SARS-CoV-2 virus. If successful, these peptides can be used to treat COVID-19. This is an important research endeavour as currently no cure or vaccines are available to combat SARS-CoV-2. We plan to use the principles of protein-protein interactions to design specific peptides that can bind to a region of viral protein S, known to be important for virus replication. This is a collaborative work with the Ottawa Hospital Research Institute (OHRI) and the University of California, San Francisco (UCSF). We plan to further test our peptides in a pseudoviral system that resembles SARS-CoV-2 infection. The continuation of this work will be to test the peptides in a mouse system.